22 July 2022 – The Federal Office of Public Health (FOPH) has signed a contract with AstraZeneca Switzerland for the procurement of around 1,200 doses of tixagevimab/cilgavimab. This is the second contract with the pharmaceutical company for the reservation of this drug. The combination drug consisting of the antibodies tixagevimab and cilgavimab, can protect at-risk individuals with weakened immune systems from a severe course of Covid-19. Originally used only for preventive use, recent studies show that this medicine is also effective in treating people who already have had Covid-19. The medicinal product is currently not authorised in Switzerland, but in accordance with Covid-19-Regulation-3, it can already be used during an ongoing authorisation procedure for the treatment of Covid-19 patients.

For more information, see here.